Bedrijfsoverzicht
Savara Inc. is a clinical stage biopharmaceutical company dedicated to addressing rare respiratory diseases within the United States market. The organization operates within the broader Healthcare sector, specifically focusing on the Biotechnology industry, which implies a high-risk, high-reward environment centered on drug discovery and development rather than established commercial sales. The company employs approximately 70 individuals and holds a market capitalization of $1.16 billion. Given that the Price to Sales ratio is N/A, the market valuation of $1.16 billion indicates that the company's market price is significantly decoupled from current revenue generation, a common characteristic for clinical-stage entities where value is derived from potential future product approvals rather than immediate cash flow. The absence of reported annual revenue in the trailing twelve months suggests the company is still in a phase of heavy investment in research and development to advance its lead product candidate, molgramostim, toward commercialization. This scale, characterized by a substantial market cap relative to its small employee base and lack of revenue, positions Savara as a speculative asset reliant on the successful progression of its Phase 3 clinical trials for autoimmune conditions.
Financiële gezondheid
The company reports a Net Income of $-118,837,000 and an EBITDA of $-122,676,000 over the trailing twelve months, while Revenue is listed as N/A. The significant gap between revenue (which is effectively zero or negligible given the N/A status) and net income reveals a cost structure dominated by operating expenses typical of clinical-stage biotechnology firms, where costs are incurred for research, clinical trials, and administrative functions without corresponding sales revenue. Free Cash Flow stands at $-55,517,876, indicating a net cash outflow that reflects the capital-intensive nature of developing new therapies and limits the company's immediate financial flexibility for external acquisitions or expansions. All three margins—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, a figure that indicates the company has not yet achieved commercial profitability and is burning cash to fund its development pipeline. Regarding liquidity, the company holds $236.59M in cash against $29.91M in debt, resulting in a Debt to Equity ratio of 14.73, which suggests a balance sheet that is heavily weighted toward equity financing rather than leverage, as the debt amount is relatively small compared to cash reserves. The Current Ratio is an exceptionally high 11.85, which indicates robust short-term liquidity and a strong ability to cover current liabilities with current assets, providing a significant safety margin against financial distress. Return on Equity is -63.4% and Return on Assets is -32.9%, metrics that reveal that management is currently generating negative returns on the capital invested in the company, a standard outcome for pre-revenue companies but one that signals a lack of profitability until the lead product candidate reaches the market.
Waarderingsbeoordeling
The Trailing P/E Ratio is N/A because the company is not profitable, while the Forward P/E is listed as -17.69. The negative forward P/E implies that the market expects the company to remain unprofitable or for earnings to be negative in the coming period, as the denominator in the earnings calculation remains negative until the company turns a profit. The Price to Book ratio is 7.06, indicating that the market values the company at more than seven times its book value, which suggests a significant market premium assigned to the potential value of its intellectual property and pipeline assets that are not yet reflected on the balance sheet. The Price to Sales ratio is N/A and the EV/EBITDA is -10.00; these alternative valuation metrics suggest that traditional multiple-based valuation models are not applicable due to the lack of earnings and revenue, forcing investors to rely on other indicators like clinical trial milestones. The stock has traded between a 52-Week High of $7.00 and a 52-Week Low of $1.89, meaning the current market price sits within this historical range, reflecting the volatility typical of biotechnology stocks dependent on binary clinical outcomes. The Beta is 0.31, which indicates that the stock price is less volatile than the broader market, suggesting that Savara's share price moves with significantly lower amplitude than the overall market index despite its high-risk business model.
Growth & Income
The Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A due to the lack of historical revenue data. Consequently, it is not possible to compare earnings growth against revenue growth rates, as the company has not yet generated commercial revenue to establish a baseline for percentage growth calculations. Regarding income distribution, the Dividend Yield is N/A and the Payout Ratio is 0.0%, indicating that the company does not pay dividends to shareholders. This lack of a dividend payout is consistent with the company's strategy of reinvesting all available earnings and cash reserves into research and development activities rather than distributing returns to investors. Since the company is in a growth phase focused on bringing molgramostim to market, the capital is directed toward advancing the drug through Phase 3 development for the treatment of autoimmune diseases rather than being returned to capital providers. The overall growth and income profile is defined by a complete absence of current commercial earnings and dividends, with value entirely dependent on the future successful commercialization of the company's pipeline.